China Resources Double-Crane Pharmaceutical Co., Ltd. is a leading integrated pharmaceutical company in China, operating as a core subsidiary of China Resources Pharmaceutical Group. The company specializes in the research, development, manufacturing, and distribution of a wide range of medical products, with a dominant position in the infusion, cardiovascular, and endocrine segments.
Historically known for its robust generic portfolio and large-scale infusion production, the company has recently pivoted toward innovation in oncology and rare diseases. It operates 23 production bases across China and maintains a comprehensive R&D infrastructure focused on small molecules and advanced formulations. The company is a key participant in China's national healthcare system, with a significant portion of its portfolio included in the National Reimbursement Drug List (NRDL).
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Chronic disease therapeutics and Intravenous infusions
SIZE & FINANCIALS
Employees:10000+
Revenue:$1B-$5B
Founded:1939
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Beijing Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical Group Limited, Harvest Fund Management, China Southern Asset Management
STOCK
Exchange:SSE
Ticker:600062
Market Cap:$2.6B
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 1 (Innovative assets); Commercial (Generics)
Modalities:Small molecule, API, Infusion solutions, Enteric-coated tablets
Active Trials:5
Trial Phases:Phase 1: 3 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:China Resources Pharmaceutical Group Limited
Subsidiaries:Anhui Double-Crane Pharmaceutical Co., Ltd., CR Saike Pharmaceutical Co., Ltd., Wuhan Binhu Double Crane Pharmaceutical Co., Ltd., CR Zizhu Pharmaceutical Co., Ltd., Guizhou Tianan Pharmaceutical Co., Ltd.
Key Partnerships:Pfizer (Oncology drug operations in China), HELP Therapeutics (Heart failure co-development)
COMPETITION
Position:Leader
Competitors:Jiangsu Hengrui Medicine, Shanghai Pharmaceuticals, Sino Biopharmaceutical, CSPC Pharmaceutical Group, Shanghai Fosun Pharmaceutical
LEADERSHIP
Key Executives:
Wenchao Lu - Chairman
Qian Zhao - President & Director
Board Members:Xiaosong Bai, Xiangming Li, Hui Xu, Maozhu Sun (Independent), Ning Liu (Independent)
LINKS
Website:dcpc.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with China Resources Double-Crane Pharmaceutical Co., Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.